Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study

Khalilpour, Atefeh; Taherahmadi, Hassan; Bagheri, Bahador

doi:10.1016/j.therap.2018.11.013

Cited by 11 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, protein pump inhibitors, such as pantoprazole, have started to be tested in clinical studies for their combined applications with an iron chelator to target iron metabolism (e.g. reduction in serum ferritin level) for patients with thalassaemia (Eghbali, Khalilpour, Taherahmadi, & Bagheri, 2019).…”

Section: Resultsmentioning

confidence: 99%

Spectroscopic study of in situ‐formed metallocomplexes of proton pump inhibitors in water

et al. 2020

View full text Add to dashboard Cite

Proton pump inhibitors, such as omeprazole, pantoprazole and lansoprazole, are an important group of clinically used drugs. Generally, they are considered safe without direct toxicity. Nevertheless, their long‐term use can be associated with a higher risk of some serious pathological states (e.g. amnesia and oncological and neurodegenerative states). It is well known that dysregulation of the metabolism of transition metals (especially iron ions) plays a significant role in these pathological states and that the above drugs can form complexes with metal ions. However, to the best of our knowledge, this phenomenon has not yet been described in water systems. Therefore, we studied the interaction between these drugs and transition metal ions in the surrounding water environment (water/DMSO, 99:1, v/v) by absorption spectroscopy. In the presence of Fe(III), a strong redshift was observed, and more importantly, the affinities of the drugs (represented as binding constants) were strong enough, especially in the case of omeprazole, so that the formation of a metallocomplex cannot be excluded during the explanation of their side effects.

show abstract

Section: Resultsmentioning

confidence: 99%

Spectroscopic study of in situ‐formed metallocomplexes of proton pump inhibitors in water

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Drugs such as liraglutide and pyridoxal 5′-phosphate (MC-1) can modulate the necrosis of cardiomyocytes by intervening calcium ions (Nauck et al, 2018;Alexander et al, 2008). Amlodipine and pantoprazole regulate ferroptosis in cardiomyocytes by affecting iron absorption (Shakoor et al, 2014;Eghbali et al, 2019) (Figure 3). Therefore, more work is needed to explore whether drugs can target therapy in various cardiac cells by handling multiple types of PCD.…”

Section: Summary and Discussionmentioning

confidence: 99%

“…Farmaki K et al also found that the combined chelation therapy of desferrioxamine and desferrioxone can prevent and reverse the cardiac complications caused by excessive iron in blood transfusion (Farmaki et al, 2010). Other clinical trials concerning iron chelators in cardiovascular diseases are shown in Supplementary Table S9 (Penckofer and Schwertz, 2000;Al-Rousan et al, 2009;Farmaki et al, 2010;Lal et al, 2013;Jansová et al, 2014;Shakoor et al, 2014;Pennell et al, 2015;Ho et al, 2017;Eghbali et al, 2019). Although iron ion chelators are manifested as a promising drug target in clinical trials, their potential molecular signaling pathways and networks remain to be explored.…”

Section: Targeting Ferroptosis In Clinical Practicementioning

confidence: 99%

Programmed Cell Death: Complex Regulatory Networks in Cardiovascular Disease

Zhou

Sun

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Abnormalities in programmed cell death (PCD) signaling cascades can be observed in the development and progression of various cardiovascular diseases, such as apoptosis, necrosis, pyroptosis, ferroptosis, and cell death associated with autophagy. Aberrant activation of PCD pathways is a common feature leading to excessive cardiac remodeling and heart failure, involved in the pathogenesis of various cardiovascular diseases. Conversely, timely activation of PCD remodels cardiac structure and function after injury in a spatially or temporally restricted manner and corrects cardiac development similarly. As many cardiovascular diseases exhibit abnormalities in PCD pathways, drugs that can inhibit or modulate PCD may be critical in future therapeutic strategies. In this review, we briefly describe the process of various types of PCD and their roles in the occurrence and development of cardiovascular diseases. We also discuss the interplay between different cell death signaling cascades and summarize pharmaceutical agents targeting key players in cell death signaling pathways that have progressed to clinical trials. Ultimately a better understanding of PCD involved in cardiovascular diseases may lead to new avenues for therapy.

show abstract

“…In particular, Eghbali et al performed a RCT on 60 patients with thalassemia major and intermedia in therapy with iron chelators. The authors demonstrated that the addition of pantoprazole to patients' therapy significantly decreased serum ferritin levels compared to control [48]. On the other hand, a study conducted on 128 patients affected by Zollinger-Ellison syndrome showed that long term use of omeprazole did not cause iron deficiency [49].…”

Section: Malabsorption and Related Complicationsmentioning

confidence: 99%

Side effects of long-term use of proton pump inhibitors: practical considerations

Castellana¹,

Pecere²,

Furnari³

et al. 2021

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

show abstract

Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study

Cited by 11 publications

References 22 publications

Spectroscopic study of in situ‐formed metallocomplexes of proton pump inhibitors in water

Spectroscopic study of in situ‐formed metallocomplexes of proton pump inhibitors in water

Programmed Cell Death: Complex Regulatory Networks in Cardiovascular Disease

Side effects of long-term use of proton pump inhibitors: practical considerations

Contact Info

Product

Resources

About